Svystemic lupus erythematosus: Multiple immunological phenotypes in a complex genetic disease

被引:143
作者
Fairhurst, Anna-Marie [1 ]
Wandstrat, Amy E.
Wakeland, Edward K.
机构
[1] Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75230 USA
[2] Univ Texas, SW Med Ctr, Div Rheumat Dis, Dallas, TX 75230 USA
来源
ADVANCES IN IMMUNOLOGY, VOL 92 | 2006年 / 92卷
关键词
D O I
10.1016/S0065-2776(06)92001-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is a complex polygenic autoimmune disease characterized by the presence of anti-nuclear autoantibodies (ANAs) that are often detectable years prior to the onset of clinical disease. The disease is associated with a chronic activation of the immune system, with the most severe forms progressing to inflammatory damage that can impact multiple organ systems in afflicted individuals. Current therapeutic strategies poorly control disease manifestations and are generally immunosuppressive. Recent studies in human patient populations and animal models have associated elements of the innate immune system and abnormalities in the immature B lymphocyte receptor repertoires with disease initiation. A variety of cytokines, most notably type I interferons, play important roles in disease pathogenesis and effector mechanisms. The genetic basis for disease susceptibility is complex, and analyses in humans and mice have identified multiple susceptibility loci, several of which are located in genomic regions that are syntenic between humans and mice. The complexities of the genetic interactions that mediate lupus have been investigated in murine model system by characterizing the progressive development of disease in strains expressing various combinations of susceptibility alleles. These analyses indicate that genetic epistasis dramatically impact disease development and support the feasibility of identifying molecular pathways that can suppress disease progression without completely impairing normal immune function.
引用
收藏
页码:1 / 69
页数:69
相关论文
共 429 条
[81]   Anti-TNF-α-induced systemic lupus syndrome [J].
Debandt, M ;
Vittecoq, O ;
Descamps, V ;
Le Loët, X ;
Meyer, O .
CLINICAL RHEUMATOLOGY, 2003, 22 (01) :56-61
[82]   Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus [J].
Denny, MF ;
Chandaroy, P ;
Killen, PD ;
Caricchio, R ;
Lewis, EE ;
Richardson, BC ;
Lee, KD ;
Gavalchin, J ;
Kaplan, MJ .
JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2095-2104
[83]   Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies [J].
Deo, YM ;
Graziano, RF ;
Repp, R ;
vandeWinkel, JGJ .
IMMUNOLOGY TODAY, 1997, 18 (03) :127-135
[84]   Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity [J].
Dörner, T ;
Lipsky, PE .
CLINICAL AND EXPERIMENTAL MEDICINE, 2005, 4 (04) :159-169
[85]   GENETIC-ANALYSIS OF THE NZB CONTRIBUTION TO LUPUS-LIKE AUTOIMMUNE-DISEASE IN (NZB X NZW)F-1 MICE [J].
DRAKE, CG ;
BABCOCK, SK ;
PALMER, E ;
KOTZIN, BL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4062-4066
[86]  
DRAKE CG, 1995, J IMMUNOL, V154, P2441
[87]   Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients [J].
Duits, AJ ;
Bootsma, H ;
Derksen, RHWM ;
Spronk, PE ;
Kater, L ;
Kallenberg, CGM ;
Capel, PJA ;
Westerdaal, NAC ;
Spierenburg, GT ;
GmeligMeyling, FHJ ;
vandeWinkel, JGJ .
ARTHRITIS AND RHEUMATISM, 1995, 38 (12) :1832-1836
[88]   MOLECULAR MAPPING OF THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX BY PULSED-FIELD GEL-ELECTROPHORESIS [J].
DUNHAM, I ;
SARGENT, CA ;
TROWSDALE, J ;
CAMPBELL, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) :7237-7241
[89]   The regulation of FasL expression -: A distinguishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE [J].
Eneslätt, K ;
Rantapää-Dahlqvist, S ;
Uddhammar, A ;
Sundqvist, KG .
JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (03) :183-192
[90]   Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα [J].
Eriksson, C ;
Engstrand, S ;
Sundqvist, KG ;
Rantapää-Dahlqvist, S .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (03) :403-407